Email ID
Password
Scrip   
Monotherapy data positive for BMS/AstraZeneca's novel antidiabetic
23 October 2009
Asher Mullard

Bristol-Myers Squibb/ AstraZeneca's antidiabetic drug dapagliflozin reduced blood glucose levels in the second of 10 Phase III trials, spurring further hopes for the first-in-class drug. It failed to induce weight loss, a secondary endpoint, however, tempering some expectations fostered by a recent...



Please Login to read the full article.
JOB OF THE WEEK Promote your vacancy here
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36